St. Jude Medical gets FDA approval for two heart-failure devices

By Elaine Rigoli

Tampa, Fla., May 16 - St. Jude Medical, Inc. announced Food and Drug Administration approval of its newest devices, the Epic 2 implantable cardioverter defibrillator (ICD) and the Epic 2 HF cardiac resynchronization therapy defibrillator, for treating patients with potentially lethal heart arrhythmias and heart failure.

Both products will be released for sale this month in the U.S. market. Both are two of more than 20 new cardiac rhythm management products being introduced this year by St. Jude Medical, the company said.

Based in St. Paul, Minn., St. Jude Medical provides medical-device technology and services for cardiac, neurological and chronic-pain patients worldwide.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.